Objective Fludarabine plus melphalan (FM) and fludarabine plus busulfan (FB) are two major conditioning regimens for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods We retrospectively analyzed patients who underwent allo-HSCT after a conditioning regimen consisting of FM or FB with/without total body irradiation for hematological malignancies between 2005 and 2014. Results There were 41 patients who met the criteria. The median follow-up time for the survivors was 3 years. Thirty-two patients received allo-HSCT after the FM regimen and nine patients received allo-HSCT after the FB regimen. Patients who received FB were older than those who received FM (p=0.041). There was no significant difference in the 3-year overall survival between patients who had received FB and those who had received FM (29.6% vs. 56.5%, p=0.267). The 3-year cumulative incidence of relapse was significantly higher in patients who had received FB than that in patients who had received FM (66.7% vs. 17.8%, p= 0.004), and FB was an independent prognostic factor for relapse by a multivariate analysis (hazard ratio, 9.8; 95% confidential interval, 2.5-39.3; p=0.001). When we restricted the evaluation to patients with acute myeloid leukemia and myelodysplastic syndrome, the 3-year cumulative incidence of relapse was also significantly higher in patients who had received FB than that in patients who had received FM (75.0% vs. 16.1%, p=0.004).
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following reduced-intensity conditioning has been increasingly used in older patients or in patients who may be unsuitable for myeloablative conditioning with the aim of reducing non-relapse mortality (NRM) (1) . Fludarabinebased regimens have been used as conditioning regimens for allo-HSCT in patients who must avoid cyclophosphamide toxicity or high-dose total body irradiation (TBI). Although fludarabine-based regimens with melphalan or busulfan have been widely used (2) (3) (4) (5) (6) (7) (8) , and there have been several retrospective reports comparing the two regimens (9) (10) (11) , there have been no randomized, controlled trials to compare these two regimens. We believed that an understanding of the current status is important to conduct prospective trials in the future. Therefore, we retrospectively studied the outcomes of allo-HSCTs after fludarabine plus melphalan (FM) and fludarabine plus busulfan (FB) conditioning regimens in a single-center analysis. 
Materials and Methods
Patients who had received FM or FB with/without TBI for hematological malignancies from September 2005 to October 2014 at Yokohama City University Medical Center (Yokohama, Japan) were retrospectively investigated. The conditioning regimen consisted of FM or FB with or without low-dose TBI at 3 Gy. TBI was not administered when transplantation was completed using a human leukocyte antigen (HLA)-matched sibling donor. We defined an HLA match as a 6/6 antigen-matched donor (HLA-A, B, DR). Short-term treatment with methotrexate and calcineurin inhibitors was used as graft-versus-host disease (GVHD) prophylaxis. Grading of acute GVHD was performed according to established criteria (12) . Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in the first complete remission or myelodysplastic syndrome (MDS) with refractory anemia was defined as a standard-risk disease. All other conditions were classified as a high-risk disease. We considered a negative cytomegalovirus serostatus for recipients and positive for donors to be a risk factor (13) .
All statistical analyses were performed with the R software program (version 3.0.1; R Development Core Team). The overall survival was calculated from the date of transplantation to the date of death from any cause or the date of the final follow-up. Survival curves were drawn according to the Kaplan-Meier method, and the significance for differences in the survival was assessed by the log-rank test. NRM was defined as death without disease relapse or the development of resistance. Death without relapse was considered to be a competing risk for relapse, relapse was a competing risk for NRM, and relapse and death without GVHD were competing risks for GVHD. NRM, relapse, and GVHD were estimated from the cumulative incidence curves, and the statistical significance of differences between the curves was assessed by Gray's test. We applied the Cox proportional hazards model for the analysis of the overall survival, while Fine and Gray's proportional hazards model was used for relapse, NRM, and GVHD. In the multivariate analysis we included risk factors which showed a tendency toward significant differences in the prognosis by a univariate analysis (p<0.1). This study was approved by the institutional review board of Yokohama City University Medical Center.
Results
A total of 41 patients received FM or FB for hematological malignancies and their characteristics are shown in Table 1. The median follow-up time for survivors was 3 years. The median age of the subjects was 57 years (range: 32-65 years), which included 28 men and 13 women. There were 32 patients who received FM and nine patients who received FB. The doses of melphalan in patients who had received FM were 80 mg/m 2 in three patients, 120 mg/m 2 in one patient, 140 mg/m 2 in 27 patients, and 180 mg/m 2 in one patient, and the doses of intravenous administration of busulfan in patients who had received FB were 6.4 mg/kg in four patients and 12.8 mg/kg in five patients. The characteristics of patients who had received FM and FB are shown in Table 1. Patients who had received FB were older than patients who had received FM (p=0.041). There was no patient with lymphoproliferative diseases among the patients who had received FB. There was no difference in sex mismatch, disease risk, performance status, hematopoietic cell transplantation comorbidity index (14) , cytomegalovirus serostatus and other transplantation conditions between the patients who had received FM and those who had received FB.
In the survival analysis, age was the only prognostic factor for the overall survival (Table 2 ). There was no significant difference in the 3-year overall survival between patients receiving FB and patients receiving FM (29.6% vs. 56.5%, p=0.267) (Table 2, Fig. 1 ). The 3-year cumulative incidence of relapse was significantly higher in patients who received FB than that in patients who received FM (66.7% vs. 17.8%, p=0.004) (Table 3, Fig. 2 ). In addition, FB was an independent prognostic factor for relapse by the multivariate analysis (hazard ratio, 9.8; 95% confidential interval, 2.5-39.3; p=0.001) ( Table 3 ). When we restricted the evaluation to patients with AML and MDS (n=24), the 3-year cumulative incidence of relapse was also significantly higher in patients who had received FB than that in patients who had received FM (75.0% vs. 16.1%, p=0.004) (Fig. 3) .
The 3-year cumulative incidence of NRM in patients who had received FB was lower than that in patients who had received FM, however, there was no significant difference (11.1% vs. 30.1%, p=0.265) (Fig. 4) . Grade II to IV acute GVHD occurred in 17 patients. There was no significant difference in the incidence of grade I-IV acute GVHD and grade II-IV acute GVHD in relation to the conditioning regimens according to a cumulative incidence analysis (p= 0.804 and p=0.565, respectively). In patients who had received FM, relapse was the most frequent cause of death, and it was related to death in 6 patients. NRMs were seen in 8 patients. The causes of death were infection in 4 patients, thrombotic microangiopathy in 2, GVHD in 1, and eating disorder in 1. In patients who had received FB, relapse was also the most frequent cause of death, and it was related to death in 4 patients. NRMs were seen in 2 patients. The causes of death were acute respiratory distress syndrome in 1 patient and cerebral infarction in 1.
We added a landmark analysis to analyze the impact of acute GVHD on relapse. There were 10 patients who died or had a relapse within 100 days after transplantation, and we analyzed 31 patients without death or relapse within 100 days after transplantation. Acute GVHD was not related to relapse (hazard ratio, 1.5; 95% confidential interval, 0.3-4.4; p=0.950) and FB was a significant risk factor for relapse (hazard ratio, 7.4; 95% confidential interval, 1.8-31.6; p= 0.006) by the univariate analysis. FB was an independent prognostic factor for relapse by the multivariate analysis, including risk factors which showed a tendency toward significant differences by the univariate analysis and acute GVHD (hazard ratio, 11.2; 95% confidential interval, 1.8-70.9; p=0.010).
Discussion
There have been some retrospective studies that have compared the two fludarabine-based regimens (9-11). Al- p=0.267
Flu+BU±TBI, n=9 though the overall survival in these reports was comparable between patients who had received FM and FB (9-11), disease control was better in patients who had received FM in some reports (9, 11) . In the present study, although there was no significant difference between the overall survival of patients who had received FM and FB, the relapse rate was lower in patients who had received FM, and the results supported the previous reports. Commonly, the administration of more than 9 mg/kg of busulfan or more than 140 mg/m 2 of melphalan is thought to indicate full-intensity condition- Flu+BU±TBI, n=8
Number at risk Flu+BU±TBI  8  4  3  2  2  1  Flu+Mel±TBI  16  11  8  7  7  6 ing (15). On the other hand, dose finding studies of busulfan (16) and melphalan (17) have been conducted, and the reported optimal dose were 11.2 mg/kg and 135 mg/m 2 , respectively. Therefore, the antitumor effect of busulfan may be lower than that of melphalan in the RIC allo-HSCT setting. In addition, the difference of relapse rates may not arise from the graft-versus-leukemia effect, but rather the antitumor effect of conditioning regimens because the rates of acute GVHD between FM and FB were similar and acute GVHD was not related to relapse in the present study. The reports by Baron et al. included only patients with AML (11) and there were no patients with lymphoid malignancies among those patients who had received FB in the present study. Kanamori et al. reported that the conditioning regimen did not have a significant impact in patients with ALL who had received reduced-intensity conditioning allo-HSCT (18) . Therefore, disease control with FM for hematological malignancies may be better in patients with myeloid malignancies and not in patients with lymphoid malignancies. A validation study particularly for patients with lymphoid malignancies is required. Although Shimoni et al. reported that there was no significant difference between FM and FB in the overall survival, they also reported that the NRM of patients who had received FM was higher than that of patients who had received FB (9) . Similarly, although there was no significant difference, the NRM of patients who had received FM was higher than that of patients who had received FB in the present study. Therefore, FM may be more toxic than FB. However, because the dose of melphalan and busulfan and the method of busulfan administration (orally or intravenously) was variable in the previous studies (9) (10) (11) and in the present study, we must confirm a regimen that contains uniform doses of FM or FB.
There are some limitations associated with the present study, such as its retrospective design, the small number of subjects, and the inclusion of both reduced-intensity and full-intensity regimens. Therefore, prospective large-scale validation studies are needed to compare patients who received FM and FB of fixed doses.
In conclusion, the results suggested that FM may provide better disease control than FB. However, large-scale prospective studies are necessary to confirm these results.
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